FDA approves use of experimental Ebola drug

THE HILL                     Oct. 6, 2014
By Sarah Ferris

Washington --The Food and Drug Administration (FDA) on Monday approved the use of an experimental drug that has been hailed as one of the pharmaceutical industry's best chances at fighting the Ebola virus.

Chimerix, a North Carolina-based biopharmaceutical company, announced Monday that it has received approval to administer an antiviral drug called brincidofovir that has successfully treated Ebola in lab tests.

The drug has also been tested by the Centers for Disease Control and Prevention and the National Institutes of Health, though it is not expected to win approval for wide public use until late 2016.

 Another drug that has been used to treat Ebola-infected patients, TKM-Ebola, has also been permitted for emergency use by the FDA.... The drug, produced by Canadian drugmaker Tekmira, was given a "fast track" designation and is still undergoing clinical trials. 

See full story

http://thehill.com/policy/healthcare/219856-fda-approves-use-of-experimental-ebola-drug